UroGen Pharma’s (URGN) “Buy” Rating Reiterated at D. Boral Capital

D. Boral Capital reissued their buy rating on shares of UroGen Pharma (NASDAQ:URGN) in a research note published on Friday,Benzinga reports. The firm currently has a $25.00 price target on the stock.

Several other research firms have also commented on URGN. EF Hutton Acquisition Co. I upgraded UroGen Pharma to a “strong-buy” rating in a research note on Monday, October 14th. HC Wainwright restated a “buy” rating and issued a $60.00 price target on shares of UroGen Pharma in a research report on Tuesday, October 15th. Oppenheimer reaffirmed an “outperform” rating and issued a $40.00 price objective on shares of UroGen Pharma in a research note on Wednesday, October 16th. Finally, Guggenheim assumed coverage on UroGen Pharma in a research note on Thursday, August 22nd. They set a “buy” rating and a $40.00 price objective for the company. Five research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, UroGen Pharma presently has an average rating of “Buy” and a consensus price target of $43.70.

UroGen Pharma Trading Up 0.7 %

UroGen Pharma stock opened at $12.29 on Friday. UroGen Pharma has a 52-week low of $10.60 and a 52-week high of $20.70. The company has a market cap of $288.25 million, a P/E ratio of -3.90 and a beta of 1.06. The company has a quick ratio of 8.77, a current ratio of 9.00 and a debt-to-equity ratio of 4.77. The business has a 50-day simple moving average of $12.28 and a two-hundred day simple moving average of $13.97.

UroGen Pharma (NASDAQ:URGN) last posted its quarterly earnings data on Wednesday, November 6th. The company reported ($0.55) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.84) by $0.29. The business had revenue of $25.20 million during the quarter, compared to analysts’ expectations of $24.22 million. During the same period in the previous year, the business posted ($0.68) EPS. Analysts predict that UroGen Pharma will post -3.1 EPS for the current year.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. Tidal Investments LLC grew its stake in UroGen Pharma by 19.1% during the third quarter. Tidal Investments LLC now owns 37,595 shares of the company’s stock valued at $477,000 after acquiring an additional 6,030 shares in the last quarter. Barclays PLC boosted its holdings in shares of UroGen Pharma by 409.3% during the 3rd quarter. Barclays PLC now owns 59,778 shares of the company’s stock valued at $759,000 after purchasing an additional 48,040 shares during the last quarter. Geode Capital Management LLC grew its position in shares of UroGen Pharma by 8.1% during the third quarter. Geode Capital Management LLC now owns 455,637 shares of the company’s stock valued at $5,787,000 after purchasing an additional 34,248 shares in the last quarter. XTX Topco Ltd bought a new stake in shares of UroGen Pharma in the third quarter worth about $297,000. Finally, State Street Corp lifted its position in shares of UroGen Pharma by 5.9% in the third quarter. State Street Corp now owns 769,583 shares of the company’s stock worth $9,774,000 after buying an additional 42,907 shares in the last quarter. 91.29% of the stock is owned by hedge funds and other institutional investors.

About UroGen Pharma

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.